X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

New analysis finds Average Sales Price system has led to significant cost savings for Medicare and seniors

By Nicole Longo  |    March 7, 2019
When Congress created the Medicare Part D program as part of the Medicare Modernization Act of 2003 (MMA), it also implemented changes to Part B to make it market based with the creation of the...   Read More

New “Prescription for Medicare” campaign focuses on impacts of wrong and right solutions for Medicare

By Juliet Johnson  |    March 6, 2019
Today, we are launching the “Prescription for Medicare” campaign which focuses on ensuring that changes made to Medicare are the right prescription for seniors. There’s a lot of talk in Washington...   Read More

Repealing Part D noninterference clause threatens access and choice for America’s seniors

By Tom Wilbur  |    March 5, 2019
For more than a decade, Medicare Part D has successfully provided seniors access to comprehensive prescription drug coverage with low and stable premiums, while negotiation within its unique...   Read More

Guest post: Hearing from patients on Rare Disease Day

By Guest Contributor  |    February 28, 2019
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...   Read More

Rare Disease Day: Unmet medical need inspires biopharmaceutical innovation

By Richard Moscicki, M.D.  |    February 28, 2019
Today is Rare Disease Day, an annual reminder of the incredible community of patients living with a rare disease. In the U.S., rare diseases are classified as conditions that affect fewer than...   Read More

Fact Check: Biologics, regulatory data protection and the United States-Mexico-Canada Agreement

By Douglas Petersen  |    February 27, 2019
There are a lot of misconceptions and inaccuracies going around about the United States-Mexico-Canada Agreement (USMCA) and its implications for biopharmaceutical innovation and medicine prices....   Read More

New data show how sharing negotiated discounts could save certain patients hundreds of dollars at the pharmacy counter

By Tiffany Haverly  |    February 25, 2019
Updated 3/5/2019 Ensuring patients receive already negotiated savings on their medicines could save certain patients across seven states up to $2,360 a year, according to new analyses from Milliman   Read More

GOBOLDLY ad showcases need to foster America’s leadership in medical innovation

By Holly Campbell  |    February 25, 2019
Today, the Pharmaceutical Research and Manufacturers of America (PhRMA) released Breakthrough, the latest chapter of GOBOLDLY advertising showcasing the extraordinary medical breakthroughs being...   Read More

Look at the facts. Drug importation is dangerous.

By Nicole Longo  |    February 22, 2019
Today, 1 in 10 medicines worldwide and up to 50 percent of drugs consumed in developing nations are counterfeit. Importation proposals would open the U.S. borders to these dangerous and...   Read More

What you need to know about the new NHE health spending projections

By Holly Campbell  |    February 22, 2019
This week, National Health Expenditure (NHE) data released by the Centers for Medicare & Medicaid Services (CMS) projected retail medicine spending grew 3.3 percent in 2018. Each year, CMS...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates